XML 78 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisition and Disposition - Additional Information (Details)
 3 Months Ended 12 Months Ended
Sep. 08, 2023
USD ($)
item
$ / shares
shares
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 02, 2024
USD ($)
item
Jun. 26, 2024
USD ($)
Mar. 01, 2024
USD ($)
Organization and Significant Accounting Policies                
Pretax profit (loss)     $ 28,507,000 $ (238,272,000) $ (291,754,000)      
TSA receivables, net     11,010,000          
TSA payables and other accrued liabilities     11,026,000          
Goodwill       943,000        
Net impairment charge     6,772,000          
Impairment charge     0 0        
Contingent consideration, current       3,300,000        
Novartis Institutes                
Organization and Significant Accounting Policies                
Impairment charge   $ 10,600,000            
UDENYCA                
Organization and Significant Accounting Policies                
Cash consideration           $ 483,400,000    
Inventory           $ 118,400,000    
UDENYCA | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]                
Organization and Significant Accounting Policies                
Number of earnout payments | item           2    
Amount of each earnout payments           $ 37,500,000    
Transaction costs incurred     6,700,000          
YUSIMRY Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]                
Organization and Significant Accounting Policies                
Cash consideration     40,000,000       $ 40,000,000  
Inventory       17,000,000        
Inventory purchase commitments             $ 17,000,000  
Gain on sale transaction     $ 22,800,000          
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]     Gain (Loss) on Sale of Interest in Projects          
Transaction costs incurred     $ 1,000,000          
Transaction costs unpaid     900,000          
Pretax profit (loss)     (3,100,000) (59,700,000) (34,400,000)      
Reimbursed for its costs and has recorded income     800,000          
TSA receivables, net     2,300,000          
TSA payables and other accrued liabilities     4,300,000          
CIMERLI ophthalmology franchise | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]                
Organization and Significant Accounting Policies                
Cash consideration     187,800,000         $ 170,000,000
Inventory       16,400,000        
Additional consideration               $ 17,800,000
Gain on sale transaction     $ 153,800,000          
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]     Gain (Loss) on Sale of Interest in Projects          
Transaction costs     $ 7,200,000          
Retention bonus     4,700,000          
Pretax profit (loss)     2,400,000 16,600,000 $ (16,700,000)      
Income under TSA     $ 1,700,000          
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]     Other Nonoperating Income (Expense)          
TSA receivables, net     $ 8,700,000          
TSA payables and other accrued liabilities     $ 6,800,000          
Surface Acquisition                
Organization and Significant Accounting Policies                
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares 0.196              
Share price | $ / shares $ 5.2831              
Contingent value right per share | item 1              
Contingent value rights payment period 10 years              
Business combination consideration transferred $ 64,596,000              
Business Combination, Number of Shares Issued to Former Employees of Acquiree shares | shares 161,100              
Goodwill $ 0              
Business Combination, Number of Out Licensed Partnership Program | item 2              
Fair value of the contingent consideration   3,800,000            
Contingent consideration, current   0            
Acquisition related costs       $ 5,100,000        
Surface Acquisition | Novartis Institutes                
Organization and Significant Accounting Policies                
Net impairment charge   $ 6,800,000            
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, General and Administrative Expense            
Impairment charge   $ 10,600,000            
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, General and Administrative Expense            
Surface Acquisition | Surface GSK Agreement                
Organization and Significant Accounting Policies                
Milestone and royalty based CVR payments (as percent) 70.00%              
Surface Acquisition | Surface's SRF114 proprietary drug product candidate                
Organization and Significant Accounting Policies                
Upfront payment based CVR payments (as percent) 25.00%              
Surface Acquisition | Surface's SRF388 proprietary drug product candidate                
Organization and Significant Accounting Policies                
Upfront payment based CVR payments (as percent) 50.00%